Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma.

Saved in:
Bibliographic Details
Title: Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma.
Authors: Prætorius K; Dept of Pediatric and Adolescent Medicine, Herlev and Gentofte Hospital, Copenhagen, Denmark., Henriksen DP; Dept of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark., Schmid JM; Dept of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark., Printzlau P; The Capital Region Pharmacy, North Zealand Hospital, Hillerød, Denmark., Pedersen L; Dept of Respiratory Medicine, Bispebjerg Hospital, Copenhagen, Denmark., Madsen H; Dept of Respiratory Medicine, Odense University Hospital, Odense, Denmark., Andersson EA; The Danish Medicines Council Secretariat, Copenhagen, Denmark., Madsen LK; The Danish Medicines Council Secretariat, Copenhagen, Denmark., Chawes BL; Dept of Pediatric and Adolescent Medicine, Herlev and Gentofte Hospital, Copenhagen, Denmark.; COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.
Source: ERJ open research [ERJ Open Res] 2021 Aug 31; Vol. 7 (3). Date of Electronic Publication: 2021 Aug 31 (Print Publication: 2021).
Publication Type: Journal Article
Journal Info: Publisher: European Respiratory Society Country of Publication: England NLM ID: 101671641 Publication Model: eCollection Cited Medium: Print ISSN: 2312-0541 (Print) Linking ISSN: 23120541 NLM ISO Abbreviation: ERJ Open Res Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2312-0541
DOI:10.1183/23120541.00306-2021